2024 - Rome - Italy

2024 - Rome - Italy

Thirty-second meeting, 26-28 June, 2024




14:00-17:00 Registration at the Conference Venue
19:00-22:00 Opening Ceremony, Welcome Reception





8:00-8:40 Registration at the Conference
8:40-8:45 Welcome by the local organizer

Carlos Garay

8:45-9:00 Welcome and Introduction

Oscar Della Pasqua and Thomas Dorlo

9:00-10:20 Generative AI & Machine Learning in Model Building

Paolo Magni & Thomas Dumortier

9:00-9:20 Lorenzo Contento Improving simulations by learning the true random effects' distribution from a population using generative machine learning
9:20-9:40 Sam Richardson Automating Population Pharmacokinetic Model Development using Machine Learning
9:40-10:00 Gilbert Koch Learning from machine learning - how to deduce a mechanism-based pharmacometrics model for serum creatinine in preterm neonates from neural ordinary differential equations
10:00-10:20 Ercan Suekuer PMx-AI Bot: Changing the way of traditional Pharmacometrics work with AI Bots
10:20-11:50 Coffee Break, Poster and Software session I
11:50-12:30 Tutorial

Martin Bergstrand

11:50-12:30 Paolo Denti Handling within-subject/between-occasion variability in longitudinal data: Common Challenges and Practical Solutions
12:30-14:00 Lunch
14:00-15:20 Integrating Real-World Data & Pharmacometrics

Pascal Girard & Oscar Della Pasqua

14:00-14:20 Pascal Chanu A disease model for Multiple Myeloma developed using Real World Data and validated on Phase 3 clinical trials
14:20-14:40 Samer Mouksassi Streamlining Clinical Development of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in Pediatric Chronic Kidney Disease Patients by Integration of Clinical Trial and Real-World Data
14:40-15:00 Luca Marzano Overcoming the discrepancies between clinical trials and real-world data of small cell lung cancer chemotherapy. A data-driven approach to learn across real-world evidence studies
15:00-15:20 Aole Zheng A Novel Approach Using Pharmacometrics/Pharmacoeconomic (PMPE) Model for Cost-effectiveness Analysis of Tacrolimus-Diltiazem Combination in Liver Transplant Patients: Evidence from Real-world Clinical Data
15:20-16:50 Coffee Break, Poster and Software session II
16:50-17:30 Improving Clinical Trials for Rare Diseases

Monica Simeoni

16:50-17:10 Alzahra Hamdan Integrated modeling of digital-motor outcomes and clinical outcome assessments using IRT: a framework for developing better outcomes for clinical trials in rare neurological diseases
17:10-17:30 Marina Savelieva Virtual Patient Cohorts using Modeling and Simulation to support drug development in rare diseases





8:30-9:45 Lewis Sheiner Student Session

Siv Jönsson, Jérémie Guedj, Coen van Hasselt

8:30-8:55 Wendy Chu Optimizing dosing strategies for post-kala-azar dermal leishmaniasis: a geographical comparison of systemic and skin pharmacokinetics and pharmacodynamics of antileishmanial drugs
8:55-9:20 Selma El Messaoudi Mechanistic modeling of the long-term dynamics of viral markers to predict the outcome of combination therapy in chronic HBV and HDV infections
9:20-9:45 Julie Dudasova Logistic regression-based approach to assess heterogeneity in vaccine efficacy using immunogenicity measurements in phase 3 clinical trials
9:45-9:50 Presentation Lewis Sheiner Student Session Awards
9:50-11:20 Cofee break, Poster and Software session III
11:20-12:40 Dose extrapolation & posology

Stefanie Hennig & Thomas Dorlo

11:20-11:40 Rik Schoemaker Quantification of the analgesic effect of intranasal coadministration of ketamine and sufentanil in adults to support the development of a pain relief treatment (CT001) in children
11:40-12:00 Sandrine Boulet Bayesian framework for multi-source data integration - application to Human extrapolation from preclinical studies
12:00-12:20 Laila Nassar Pharmacokinetics During Hemodialysis and Hemodiafiltration: Dialysis Clearance is more important than Dialysis Efficiency - Application to Amikacin
12:20-12:40 Davide Bindellini From physiology to disease: A quantitative framework for system-disease-drug interaction in cortisol replacement therapy
12:40-14:10 Lunch
14:10-14:50 Protein Drugs & Degraders

Rocío Lledó-García

14:10-14:30 Javier Sanchez Fernandez Optimizing Molecule Design for Bispecific Antibodies in Immuno-Oncology: A Case Study with FAP-4-1BBL
14:30-14:50 Robin Haid Transforming the discovery of targeted protein degraders: the translational power of predictive PK/PD modeling
14:50-15:00 ISoP Update

Vijay Ivaturi

15:00-16:30 Coffee Break, Poster and Software session IV
16:30-17:30 Stuart Beal Methodology Session

Gilbert Koch & Marylore Chenel

16:30-16:50 Auriane Gabaut High-dimension Mechanistic Model Building using LASSO Approaches : Application to Ebola Vaccination
16:50-17:10 Nelleke Snelder Time-varying covariates, mediation analysis and overadjustment bias in PK/PD modelling
17:10-17:30 Mohamed Tarek Make models great again by optimally restricting parameters to make non-identifiable models provably identifiable
20:00-01:00 Gala Dinner





9:15-10:15 Vaccines & Antibiotics

France Mentré & Zinnia Parra Guillén

9:15-9:35 Lorenzo Dasti A Quantitative System Pharmacology model for the development and optimization of mRNA vaccines.
9:35-9:55 Erwin Dreesen A patient stratification tool for selecting tuberculosis treatment regimen composition and duration
9:55-10:15 Carlos Olivares Mathematical Modeling Of Gut Microbiota Diversity Under The Effects of Beta-lactam Antibiotics
10:15-10:20 Preview of PAGE 2025
10:20-11:05 Coffee Break
11:05-11:45 Oncology

Ana Ruiz

11:05-11:25 Ruben Taieb Mechanistic modelling of tumor kinetics coupled with biomarker dynamics for survival prediction in non-small cell lung cancer patients
11:25-11:45 Elisabeth Rouits Incorporating clinical utility and Pharmacokinetics (PK)/Pharmacodynamics (PD) in clinical development of oncology drug candidate with a Bayesian decision analysis perspective in the context of OPTIMUS initiative
11:45-11:55 Closing Remarks